Is Mirtazapine an SSRI? How It Actually Works

Mirtazapine is not an SSRI. It belongs to a different drug class entirely, called NaSSA (noradrenergic and specific serotonergic antidepressant), and it raises serotonin and norepinephrine levels through a mechanism that has almost nothing in common with how SSRIs work. The confusion is understandable because both drug types are prescribed for depression and both affect serotonin, but the resemblance stops there. The pharmacological differences between mirtazapine and SSRIs explain why they have such different side-effect profiles, why they are sometimes prescribed together, and why mirtazapine can help with problems that SSRIs cannot.

What SSRIs Do and Why Mirtazapine Does Not Qualify

SSRIs work by blocking the reuptake pump that pulls serotonin back into the nerve cell after it has been released. By blocking that pump, more serotonin stays in the gap between nerve cells (the synapse), which is thought to improve mood over time. Common SSRIs include fluoxetine (Prozac), sertraline (Zoloft), and citalopram (Celexa). The name “selective serotonin reuptake inhibitor” describes this single, targeted action.

Mirtazapine does not block serotonin reuptake at all. Instead, it works by blocking a different set of receptors, primarily alpha-2 adrenergic receptors on nerve cells. These receptors normally act as brakes on the release of both norepinephrine and serotonin. When mirtazapine blocks those brakes, the nerve cells release more of both chemicals into the synapse.¹ Animal studies confirmed that mirtazapine enhances serotonin signaling specifically by blocking alpha-2 adrenergic auto- and heteroreceptors, which increases the firing activity of both norepinephrine and serotonin neurons.² So rather than keeping serotonin around longer (the SSRI approach), mirtazapine coaxes the brain into releasing more of it in the first place.

The Second Half of the Mechanism

Blocking alpha-2 receptors is only part of what mirtazapine does. It also directly blocks two specific serotonin receptor subtypes: 5-HT2 and 5-HT3.¹ This matters because SSRIs flood all serotonin receptors indiscriminately, and stimulation of 5-HT2 and 5-HT3 receptors is responsible for many of the side effects people dislike most about SSRIs: sexual dysfunction, nausea, agitation, and insomnia. By blocking those particular receptors while increasing overall serotonin release, mirtazapine channels serotonin activity toward the 5-HT1 receptor subtype, which is thought to be the one most relevant to antidepressant effects.

This selective blocking also explains why mirtazapine is sometimes added on top of an SSRI. Research has shown that combining a drug with strong 5-HT2 receptor-blocking properties (like mirtazapine) with an SSRI can enhance the therapeutic response beyond what either drug achieves alone, both in major depression and in treatment-resistant obsessive-compulsive disorder.³ The two drugs essentially complement each other: the SSRI raises serotonin levels across the board, and mirtazapine blocks the receptors you do not want overstimulated.

Why Mirtazapine Makes You Sleepy and Hungry

If you have ever taken mirtazapine or talked to someone who has, the two side effects you hear about first are drowsiness and increased appetite. These come from yet another receptor interaction that SSRIs do not share. Mirtazapine binds strongly to histamine H1 receptors, the same receptors targeted by antihistamine allergy medications like diphenhydramine (Benadryl).⁴ Blocking H1 receptors causes sedation and increases appetite, which is why drowsiness and weight gain are the most commonly reported side effects. In one analysis, mirtazapine was associated with an average weight increase of about 1.7 kilograms in the first 12 weeks, driven by H1 and serotonin 5-HT2C receptor blockade increasing food intake.⁵

Here is where things get counterintuitive: the sedation tends to be worse at lower doses. At lower doses, mirtazapine’s affinity for histamine receptors dominates because it binds to them more readily than to the adrenergic receptors that promote alertness. As the dose increases, the adrenergic effects kick in more strongly and partially counteract the sedation. This inverse relationship between dose and sleepiness is well documented, though it tends to fade after the first week of use regardless of dose.⁶ This is one of the most commonly misunderstood aspects of the drug. Patients prescribed a low starting dose sometimes assume that going higher will make the drowsiness unbearable, when in practice it often goes the other way.

Sexual Side Effects Compared to SSRIs

One of the most practical reasons clinicians choose mirtazapine over an SSRI is sexual dysfunction, or rather the lack of it. SSRIs are notorious for causing problems with libido, arousal, and orgasm, and these side effects are a leading reason people stop taking their antidepressant. In a naturalistic study comparing several newer antidepressants, the rates of sexual dysfunction were striking: about 60% for citalopram, 54% for venlafaxine, 54% for paroxetine, and 46% for fluoxetine, compared to roughly 18% for mirtazapine. Regression analysis confirmed that mirtazapine carried a significantly lower probability of sexual dysfunction than the SSRIs studied.⁷

The reason ties back to the mechanism. SSRI-induced sexual dysfunction is largely driven by overstimulation of 5-HT2 and 5-HT3 receptors. Since mirtazapine blocks those receptors rather than flooding them, it sidesteps most of the problem. For people who respond well to antidepressants but cannot tolerate the sexual side effects of an SSRI, mirtazapine is one of the standard alternatives clinicians reach for.

Faster Onset Than SSRIs

SSRIs typically take four to six weeks to reach full effectiveness. Mirtazapine appears to work faster, at least in the early weeks. A Cochrane systematic review of 12 trials with over 2,600 patients found that mirtazapine was significantly more effective than SSRIs at the two-week mark, though the gap narrowed by the end of standard acute treatment.⁸ A separate meta-analysis of individual patient data from 15 controlled trials showed that mirtazapine-treated patients had a 74% higher likelihood of achieving remission during the first two weeks compared to those on SSRIs.⁹

A head-to-head prospective trial against sertraline confirmed this pattern: mirtazapine produced significantly greater improvements in depression scores at every assessment during the first two weeks, after which the two drugs performed similarly.¹⁰ So mirtazapine does not necessarily outperform SSRIs in the long run, but it appears to get traction sooner. For someone in acute distress, those first two weeks matter.

Effects on Sleep

The histamine-blocking sedation that some people experience as a nuisance is, for others, the whole point. Mirtazapine is frequently prescribed when depression coexists with insomnia. A pilot study in depressed patients found that mirtazapine significantly decreased the time it took to fall asleep and significantly increased total sleep time and sleep efficiency within the first week, with the improvements holding through week two. Interestingly, it did not significantly alter REM sleep parameters, which sets it apart from many other antidepressants that tend to suppress REM sleep.¹¹

This combination of properties, improving sleep without disrupting its architecture, is uncommon among antidepressants. SSRIs in particular often worsen insomnia in the first weeks of treatment and can suppress REM sleep long-term. For someone whose depression manifests primarily as sleep disruption and low appetite, mirtazapine addresses the depression alongside both of those symptoms simultaneously.

Drug Interactions and Why They Differ from SSRIs

SSRIs are well known for interacting with other medications because several of them strongly inhibit liver enzymes (the cytochrome P450 system) that break down other drugs. Fluoxetine and paroxetine, for example, are potent inhibitors of CYP2D6 and can significantly raise blood levels of drugs processed by that enzyme. Mirtazapine is different. In vitro studies have shown that it does not substantially inhibit the major cytochrome P450 enzymes, including CYP1A2, CYP2D6, CYP3A4, CYP2C9, and CYP2C19.¹²

Mirtazapine itself is broken down by multiple enzymes, primarily CYP2D6, CYP1A2, and CYP3A4, with each enzyme handling different metabolic pathways. Because several enzymes share the workload, losing one pathway (due to a genetic variation or a drug interaction) does not dramatically alter how quickly mirtazapine is cleared from the body.¹³ This redundancy is a practical advantage for people taking multiple medications, which is common in depression.

Mirtazapine is actually a mixture of two mirror-image molecules (enantiomers), called R-mirtazapine and S-mirtazapine, which have somewhat different pharmacological effects. Research has found that cardiovascular effects like changes in heart rate and blood pressure correlate more strongly with the R-enantiomer, while sedation tracks with both.¹⁴ People who are ultra-rapid metabolizers of CYP2D6 may clear one enantiomer faster than the other, which could shift the balance of side effects. This is an active area of pharmacogenomic research.

“California Rocket Fuel” and Combination Strategies

The nickname “California Rocket Fuel” refers to the combination of mirtazapine with venlafaxine (an SNRI), a pairing used in treatment-resistant depression.¹⁵ The logic is that venlafaxine blocks reuptake of both serotonin and norepinephrine, while mirtazapine increases the release of both and selectively blocks certain serotonin receptors. The two drugs hit the same neurotransmitter systems from opposite angles, which can produce a stronger antidepressant effect than either drug alone.

Mirtazapine is also commonly combined with SSRIs for similar reasons. If someone has partially responded to an SSRI but has not reached remission, adding mirtazapine can boost both the serotonergic and noradrenergic signals while reducing the SSRI’s 5-HT2-mediated side effects. This combination approach is one of the reasons prescribers need to understand that mirtazapine is not an SSRI: giving a patient two SSRIs would just be doubling down on the same mechanism, while adding mirtazapine introduces complementary pharmacology.

Nausea and the 5-HT3 Connection

Mirtazapine’s blockade of 5-HT3 receptors is pharmacologically similar to what dedicated anti-nausea drugs like ondansetron (Zofran) do. This has led to interest in mirtazapine as an antiemetic, particularly in patients who also have depression or anxiety. Case reports and small studies have described it as a successful treatment option for severe nausea and vomiting, leveraging the 5-HT3 antagonism that comes built into its pharmacology.¹⁶ For patients dealing with nausea alongside depression, mirtazapine can address both problems with a single medication, which matters when pill burden is already high.

Appetite Stimulation Beyond Depression

The appetite-boosting effect that comes from H1 and 5-HT2C blockade has drawn attention in oncology and palliative care, where cancer-related loss of appetite and wasting (cachexia) are serious problems. A randomized trial in patients with non-small cell lung cancer found that after four weeks, the mirtazapine group consumed about 379 more calories per day than the placebo group, with significant increases in protein, carbohydrate, and fat intake.¹⁷ A smaller phase II trial showed that about a quarter of cancer patients gained at least one kilogram after four weeks on mirtazapine.¹⁸

However, a more recent phase III trial in patients with advanced cancer and cachexia found that mirtazapine did not improve appetite, body weight, grip strength, or quality of life compared to placebo, leading the authors to conclude it should not be routinely recommended for cachexia.¹⁹ The evidence is genuinely mixed on this front. Mirtazapine may help with appetite loss in some contexts, but it is not a reliable fix for cancer-related wasting, and clinicians are still sorting out who benefits.

Mirtazapine in Older Adults

Mirtazapine is commonly prescribed to elderly patients, partly because its sedating and appetite-stimulating properties can be useful in a population that frequently deals with insomnia and poor nutrition. Its low potential for drug interactions is another advantage when managing patients on multiple medications. But the evidence for safety in older adults is more nuanced than it might appear.

A large observational study comparing mirtazapine to sertraline in older people living in long-term care facilities found a mixed picture. Mirtazapine users had a modestly higher risk of dying (about 16% higher) compared to sertraline users. On the other hand, after 90 days of use, mirtazapine users had a substantially lower risk of falls and fractures: roughly 26% fewer falls and 36% fewer fractures than the sertraline group. There was no meaningful difference in cardiovascular events between the two drugs.²⁰ The higher mortality signal is concerning and not fully explained, though it may relate to prescribing patterns (sicker patients being more likely to receive mirtazapine) rather than a direct drug effect. The lower fracture rate, likely a consequence of less SSRI-related bone density loss, is a genuine clinical advantage in a population where a broken hip can be life-threatening.

Mirtazapine’s Relationship to Mianserin

Mirtazapine was developed as a chemical modification of mianserin, an older antidepressant that was already known to work through alpha-2 adrenergic blockade. Research into the neurochemistry of both drugs showed that their antidepressant effects came from stimulating the release of norepinephrine into the synapse, a concept that gained widespread acceptance. The idea that they also worked by increasing serotonin release was more contested and took longer to establish.²¹ Mirtazapine retained mianserin’s alpha-2 blocking action while adding the specific serotonin receptor (5-HT2 and 5-HT3) blockade that defines its modern profile. With sustained treatment over three weeks, animal studies showed that mirtazapine produced a lasting increase in serotonin neuron firing, confirming that the serotonergic component was not just a lab artifact but persisted with ongoing use.²²

Mirtazapine in Veterinary Medicine

One of the more unexpected uses of mirtazapine is in cats. A transdermal formulation (applied to the inner ear flap) is FDA-approved for managing weight loss in cats, making mirtazapine one of the few psychiatric medications to cross over into routine veterinary use. A survey of cat owners using mirtazapine transdermal ointment found that the most common reasons for prescribing it were chronic kidney disease (about 32% of cases), chronic digestive problems (18%), and liver disease (12%).²³ The same appetite-boosting mechanism that causes weight gain in human patients turns out to be exactly what a cat with kidney failure needs. Veterinarians who prescribe mirtazapine are exploiting the same H1 and 5-HT2C receptor pharmacology that psychiatric prescribers try to manage as a side effect.